Post
4DMT’s CF gene therapy posts early cues for improving patient outcomes
The use of 4D Molecular Therapeutics’ (4DMT) aerosolised gene therapy 4D-710 has improved the quality-of-life and spirometry-measured outcomes in three …
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as …
GenScript ProBio and CCS partner for cell and gene therapies development
GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate …
UK’s MHRA expands approval for Merz Therapeutics’ XEOMIN
The UK’s medicines and healthcare products regulatory agency (MHRA) has granted approval for a new indication for Merz Therapeutics’ XEOMIN …
Mendus and NorthX to establish cell therapy manufacturing unit
Mendus has entered an alliance with NorthX Biologics to co-establish a cell therapy manufacturing unit for its lead asset, vididencel, …
FDA grants orphan drug designation to DTx Pharma’s CMT1A therapeutic
The US Food Drug Administration (FDA) has granted orphan drug designation to DTx Pharma’s investigational DTx-1252 for the treatment of …
The rise and rise of ESG in the pharmaceutical sector – is a zero-waste supply chain possible?
Firms in the pharmaceutical industry – as with those in many advanced sectors – have become increasingly preoccupied with environmental, …
Why data management and decision-making go hand-in-hand in clinical research
The pharmaceutical industry is fuelled by data. Huge amounts of information are available from sources as diverse as patient health …
EC grants marketing authorisation for GSK’s RSV vaccine Arexvy
The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 …
Hopewell Therapeutics raises funds for genomic medicines development
Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted …
Deal of the week: Strive Health raises $166m to aid kidney health services
Each week, Pharmaceutical Technology’s editors select a deal that illustrates the themes driving change in our sector. The deal may not …
AstraZeneca ends Phase IV Andexxa trial after positive results
AstraZeneca has announced it would stop Andexxa’s Phase IV trial after the study achieved its aims earlier than expected. The ANNEXA-I …
EU agencies back Covid-19 vaccine update ahead of autumn campaign
Covid-19 vaccine compositions should be updated to provide protection against XBB Omicron variant strains in preparation for the autumn vaccination …
Baudax Bio reports promising additional data for neuromuscular blockade agent
Baudax Bio revealed has additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients …
ZyVersa Therapeutics inches closer to European patent approval for VAR 200
ZyVersa Therapeutics has received a notice of intention to grant from the European Patent Office for its patent application for …